

FOR IMMEDIATE RELEASE  
CONTACT:  
Bill Donaldson, C.E.O.  
(414) 975-5005  
(william.donaldson@estrigenix.com)  
<https://www.estrigenix.com/>



## **Drug Discovery Company Gains Funding from Concordia Angel Network** Collaboration of Three Area Professors Exploring New Treatment Options for Menopause & Alzheimer's

MILWAUKEE, May 3, 2022: Estrigenix Therapeutics, Inc., a Wisconsin-based drug discovery company, has secured a \$150,000 investment from the *Concordia Angel Network*, associated with CU Ventures ([cuventures.com](http://cuventures.com)). The SAFE—Simple Agreement for Future Equity— investment has allowed the company to lease space at the Accelerator Building at UWM's Innovation Campus to expand their research in estrogen biology, and to advance their drug lead candidate closer to human clinical trials. These early funds will increase the chances for Estrigenix to gain additional funding that is needed to perform the preclinical studies needed to secure FDA regulatory approval, for Phase 1 and 2 human clinical trials.

Estrigenix Therapeutics was formed in 2018 as a spin out from collaboration research of three Milwaukee area university scientists: Acting CEO – William Donaldson, Professor Emeritus, Marquette University; Chief Scientific Officer – Karyn Frick, Distinguished Professor of Psychology and Neurosciences Area Head at the University of Wisconsin-Milwaukee and an Adjunct Professor of Pharmacology and Experimental Therapeutics at the Medical College of Wisconsin; and Vice President of Business Development – Daniel Sem, Vice Provost for Research and Innovation, Professor of Business and Professor of Pharmaceutical Sciences at Concordia University Wisconsin.

“We are working on a compound to specifically help menopausal women to address hot flashes and memory dysfunction, which may also decrease the likelihood for the development of Alzheimer's disease in women,” said CSO Karyn Frick.

“We're very grateful to the CU Ventures and their Executive Vice President, Curt Gielow, for helping us consolidate our research efforts at Innovation Campus. This will allow Estrigenix to move our research forward to gather necessary pharmacokinetic and safety data on our drug lead and increase our ability to gain additional funding. Ultimately, this initial funding boost will lead Estrigenix to fulfilling two goals: first, developing effective treatment options for hot flashes and memory dysfunction that do NOT increase risks for the development of breast cancer, and second understanding how and why Alzheimer's is more common in women than men,” said Acting CEO Bill Donaldson.

“CU Ventures and our affiliated *Concordia Angel Network* is pleased to be supporting Estrigenix Therapeutics in this exciting development and look forward to continuing to support their drug development efforts,” said Curt Gielow, Executive VP, CU Ventures.

Estrigenix Therapeutics, a privately held pharmaceutical company, is leading the way in research and progress in estrogen biology. The company's research is focused on a compound to specifically help menopausal women alleviate hot flashes and improve memory, and potentially prevent the symptoms of Alzheimer's disease from developing.